MannKind Corporation (MNKD)

NASDAQ

$5.95

+$0.01 (0.17%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$5.83$6.00

Open $5.96

52 Week Range

$3.38$7.07

Previous Close $5.94

Market Cap1.83B

Volume2.56M

Avg Volume3.98M

P/E (TTM)55.32

EPS (TTM)$0.11

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for MannKind Corporation

DEC12025

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

Source: GlobeNewsWire•14 days ago

If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 seconds Would potentially provide a cost-effective and convenient option to address episodes of fluid buildup at...

NOV112025

MannKind to Present at the Jefferies Global Healthcare Conference

Source: GlobeNewsWire•34 days ago

DANBURY, Conn. and WESTLAKE VILLAGE, Calif....

NOV102025

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

Source: GlobeNewsWire•35 days ago

MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation suspension for nontuberculous mycobacterial (NTM) lung disease, following a futility determination based on medical monitoring...

NOV62025

MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

Source: GlobeNewsWire•39 days ago

$100,000 in scholarship funds to be distributed to at least 10 students living with diabetes pursuing higher education in life sciences Alfred E. Mann Charities and MannKind are partnering with The Diabetes Link to launch the effort in November for D...

NOV52025

MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

Source: GlobeNewsWire•40 days ago

Q3 2025 revenues of $82.1M, +17% v. Q3 2024 YTD 2025 revenues of $237.0M, +14% v....

OCT292025

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

Source: GlobeNewsWire•47 days ago

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its third quarter 2025 financial results will be released before the market opens on November 5, 2025....

OCT132025

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

Source: GlobeNewsWire•63 days ago

If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapy sBLA submission based on data from the Phase 3 INHALE-1 study PDUFA target action date of May 29, 2026 WESTLAKE VILLAGE, Calif. and ...

OCT72025

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

Source: GlobeNewsWire•69 days ago

DANBURY, Conn. and BURLINGTON, Mass....

OCT72025

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

Source: GlobeNewsWire•69 days ago

DANBURY, Conn. and BURLINGTON, Mass. , Oct. 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPharmaceuticals is expected to div...

SEP292025

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

Source: GlobeNewsWire•78 days ago

WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan...